recombinant human papillomavirus 14-valent vaccine SCT1000

A recombinant, 14-valent, human papillomavirus (HPV) vaccine, with potential immunoprotective and antineoplastic properties. Upon administration, recombinant HPV 14-valent vaccine SCT1000 may generate humoral and cellular immunity against 14 types of HPV antigens, including types 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59, thereby preventing infection upon exposure to these 14 types of HPV. In addition, this agent may stimulate cellular immune response against various cancers and genital warts associated with HPV infection.